Calypte HIV Test Gets OK in Kenya
March 30, 2006
On Tuesday, Calypte Biomedical Corp. said its oral and blood rapid-result HIV tests have been approved for sale in Kenya. Kenya, a nation of more than 30 million, including 1.2 million HIV-positive people, now has more than 350 registered sites where residents can receive HIV testing and counseling. The approval means Calypte can compete for Kenyan government contracts, anticipated to be announced later this year, for more than 4 million tests. The company said the United States is expected to provide more than $200 million in HIV/AIDS funding this year for Kenya, which is one of the 15 nations targeted by President Bush's Emergency Plan for AIDS Relief.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.